Choreo LLC bought a new stake in Bio-Techne Co. (NASDAQ:TECH – Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,311 shares of the biotechnology company’s stock, valued at approximately $309,000.
Several other hedge funds have also made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its stake in Bio-Techne by 92.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,746,119 shares of the biotechnology company’s stock valued at $404,470,000 after acquiring an additional 2,755,065 shares during the last quarter. Brown Capital Management LLC raised its stake in shares of Bio-Techne by 12.4% during the fourth quarter. Brown Capital Management LLC now owns 3,550,990 shares of the biotechnology company’s stock worth $273,994,000 after purchasing an additional 392,986 shares during the last quarter. Mairs & Power Inc. lifted its holdings in shares of Bio-Techne by 0.8% during the fourth quarter. Mairs & Power Inc. now owns 3,079,483 shares of the biotechnology company’s stock worth $237,613,000 after purchasing an additional 25,903 shares during the period. Bank of New York Mellon Corp grew its position in Bio-Techne by 14.0% in the 1st quarter. Bank of New York Mellon Corp now owns 2,862,526 shares of the biotechnology company’s stock valued at $201,493,000 after buying an additional 351,645 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in Bio-Techne by 20.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,714,994 shares of the biotechnology company’s stock valued at $122,879,000 after buying an additional 290,510 shares during the period. Institutional investors and hedge funds own 98.95% of the company’s stock.
Bio-Techne Trading Up 0.7 %
Shares of TECH stock opened at $75.28 on Wednesday. Bio-Techne Co. has a fifty-two week low of $51.79 and a fifty-two week high of $85.57. The company has a quick ratio of 2.75, a current ratio of 3.87 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $74.98 and a 200-day simple moving average of $73.89. The stock has a market cap of $11.86 billion, a P/E ratio of 59.90, a P/E/G ratio of 4.95 and a beta of 1.27.
Bio-Techne Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Monday, August 19th were given a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.43%. The ex-dividend date was Monday, August 19th. Bio-Techne’s payout ratio is 25.40%.
Analyst Upgrades and Downgrades
Several analysts have recently commented on TECH shares. Royal Bank of Canada reduced their target price on shares of Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a research note on Thursday, August 8th. Citigroup lowered Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 price objective on the stock. in a report on Wednesday, May 22nd. Robert W. Baird increased their target price on Bio-Techne from $81.00 to $82.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Finally, Benchmark restated a “buy” rating and issued a $95.00 price target on shares of Bio-Techne in a research note on Tuesday, August 13th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Bio-Techne currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.60.
Get Our Latest Stock Analysis on TECH
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Featured Articles
- Five stocks we like better than Bio-Techne
- What are earnings reports?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is Insider Trading? What You Can Learn from Insider Trading
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Insider Buying Explained: What Investors Need to Know
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. (NASDAQ:TECH – Free Report).
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.